Food firms slash salt and sugar by nearly a third
But UK manufacturers across the sector are calling for more funding and 'bold action' to help drive further innovation in healthy eating.
The Food and Drink Federation (FDF) said research by Kantar Worldpanel showed products made by its members have 31% less salt, 30% less sugar and a quarter fewer calories than they did 10 years ago.
The group – whose members make a quarter of all food and drink sold in the UK – said the progress comes after years of investment by the industry, including around £180 million in healthier product innovation in 2024 alone.
But the FDF said rising cost and regulation pressures are putting this investment under pressure, with a recent survey of its members showing 41% are planning to scale back spend on this as a result.
It wants extra funding support and is urging the Government to take 'bold, co-ordinated action across the whole food system' to help with the shift towards healthier food.
'This includes mandatory reporting on the sales of healthier and less healthy products across manufacturing, retail and hospitality,' the FDF said.
'It also means taking a more consistent approach to health policy across the entire food chain, ensuring consumers have access to the same clear information that helps them to make healthier choices, no matter where they're eating,' it added.
As well as funding for research and development and science support to the food sector, it believes the Government should help smaller firms more, with a similar scheme to the Scottish Government's Reformulation for Health programme.
Efforts so far by the industry have included changing recipes and portion sizes.
Some manufacturers have added extra portions of vegetables, while others have invested in new machinery to make changes to the cooking process and recipe.
Karen Betts, chief executive of the FDF, said: 'Companies have made major progress in slashing the calories, salt and sugar in everyday food and drink – making the food people love better for them, alongside hugely expanding the range of healthy options.
'But tackling poor diets and lifestyles is a complex issue and needs a more joined-up approach.
'We're calling on the Government today to work in a more structured partnership with the entire food industry to deliver change.'
She added that 'holistic and co-ordinated action will help us truly move the needle on this critical health challenge'.
A government spokesperson said: 'As part of this government's Plan for Change, we are committed to achieving our health mission to build an NHS fit for the future, which includes shifting from sickness to prevention.
'We are working closely with the food industry to improve people's diets and reduce levels of obesity and have already restricted junk food advertising on TV and online as well as limiting school children's access to fast food outlets.
'Making healthier choices easier is a major part of creating a food environment that is fairer, with the fewest lives lost to the biggest killers and where everyone lives well for longer.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
7 hours ago
- Yahoo
'I'm seeing young people in their 20s wearing nappies because of ketamine - I need to talk about it'
Young adults are wearing pads and nappies because of ketamine use, a business owner has said. Paige Loraine who runs The Pelvic Floor Clinic said she has had over 100 people contact her about pelvic floor and bladder issues as a result of using the drug. The 32-year-old set up the business in March last year. And since then she says she received dozens of enquiries from people about symptoms related to ketamine, including parents asking for their teenage and young adult children. The mum highlighted the issue in a TikTok video which has now been viewed more than 84,000 times, reports the Liverpool Echo. READ MORE: 'Mounjaro literally saved my life. It felt only right I honour it' READ MORE: Strictly Come Dancing's Nick Knowles' wife says she 'doesn't recognise herself' in health update In the video, she said: "I need to talk about this. So ketamine is ruining lives and it is not just mentally. I am seeing young men and women in their 20s wearing pads and even nappies because of the damage it's caused to their bladder and pelvic floor. Never miss a story with the MEN's daily Catch Up newsletter - get it in your inbox by signing up here "So it's leading to bladder leakages, urgency, erectile dysfunction, pain during intimacy and a complete loss of control in day-to-day life. So chronic ketamine use can seriously weaken the pelvic floor. No one's talking about this side of it." Paige she remembers the first call she received about ketamine misuse. She said: "It was a mum for her daughter. "She just lost her way and become addicted to the ket. She was on it every day. She'd come clean off it but she was literally wearing nappies because of the damage." Ketamine is an anaesthetic for humans and animals, but is illegal for use recreationally. It is a Class B drug, making it illegal to have for yourself, give away or sell. The latest government figures show that the drug's usage among 16-24 year olds in England has tripled since 2016. Around 269,000 people aged 16-59 reported using ketamine in the year ending March 2024. Join the Manchester Evening News WhatsApp group HERE Chronic ketamine use has been linked to a number of serious health issues, including bladder damage and raising heart rate. Paige added: "I just imagine it being my kids. I just think it's awful. A bit more awareness needs to be raised about it because I don't think people realise how serious it is and I don't think kids realise how bad the drug is. "And it's only now that these things are happening because it's a taboo subject of bladder leaks and stuff. Not many people speak about it, so they're not aware of them side effects when they're taking it because no one wants to say they're weeing themselves or wearing nappies. "My purpose for doing this is for raising awareness. First, it started because one in three women suffer with pelvic floor and bladder problems and leaks. "But now, it's the epidemic of ketamine use. That's become part of my purpose as well. I'm all about raising awareness for women's and men's health." Through her business, based in Wallasey in Merseyside, Paige supports men and women with pelvic floor strengthening, bladder control and vaginal tightening. This includes treatment for women who are postpartum or going through menopause. The pelvic floor specialist does this through non invasive physiotherapy treatment called the Magic Chair. The chair works by giving off the equivalent to 12000 kegel exercises using electromagnetic stimulation. Paige also uses a non-surgical solution for vaginal tightening, pelvic floor strengthening, and improved intimate health called the 360 Magic Wand treatment.
Yahoo
8 hours ago
- Yahoo
3 simple ways to spot fake weight loss jabs after Mounjaro price hike
With the price of Mounjaro set to almost triple in the UK, there are fears more and more people will turn to counterfeits. A former Big Brother star has said she "thought she was going to die" after taking a "fake" weight loss jab amid fears of a spike in black market demand as the price of Mounjaro is due to almost triple in the UK. Aisleyne Horgan Wallace told Good Morning Britain she suffered an adverse reaction when she bought the jab online. She said she temporarily lost her sight in one eye, suffered extreme vomiting and was in excruciating pain from the jab. Wallace said she took several doses before one left her bedridden and in and out of consciousness for several days. She has now warned about the dangers of counterfeit jabs after admitting it was a "foolish thing to do." Their high cost and limited availability have led to a flourishing black market for fake jabs. The National Pharmacy Association has warned about the risk of buying the jabs online without consulting a medical professional. In May, ITV News analysed some fake jabs they acquired at a "skinny jab party" and found they contained none of the active ingredients that contribute to weight loss. But there are fears that black market problems will get worse before they get better as Mounjaro's producer, Eli Lilly, is set to increase prices in the UK. Eli Lilly has said it will increase its prices in the UK from September after Donald Trump ramped up pressure on US pharmaceutical companies. The US president has promised to stop the disparity between what Americans pay for US-produced drugs compared to other countries, which often pay far less. The Rand Corporation think tank has said that US consumers pay three times more for drugs than in other developed countries. Trump has urged companies to close the gap and has threatened reprisals for those who do not do it voluntarily. There are fears that, rather than lowering the US price, drug companies will just raise their global price to meet Trump's demands, as appears to be the case with Eli Lilly. How much is Mounjaro increasing? Eli Lilly has said it will increase the price of the drug from September by 170%. A month's supply of the highest dose is rising from £122 to £330. Eli Lilly said the NHS would not pay for a higher price, so it will still be prescribed for people with obesity and type 2 diabetes. It will be the people who buy the jab privately through pharmacies or online stores that pay the higher price. The company has said private healthcare providers will be able to negotiate their own prices for purchasing the drug. Mounjaro is seen as the best weight-loss drug available by some, although Wegovy, made by Danish company Novodisk, has seen a huge surge in demand as a result of the price rises. A trial comparing the drugs found that people who took Mounjaro over 72 weeks lost 22.8kg compared to 15kg for people who took Wegovy. This has all led to a surge in people being uncompromising in their desire for Mounjaro and has led to many looking for alternative ways to secure their jabs. Medical professionals warn about people turning to counterfeits The price increase has led to people purchasing as many Mounjaro jabs as possible, but medical professionals have warned to be careful where you buy them from. Professor Claire Anderson, president of the Royal Pharmacist Society (RPS), told the Independent: "Counterfeit medicines from unregulated sources pose serious health risks - they can contain incorrect doses, harmful substances or no active ingredient at all." Jason Murphy, Head of Pharmacy at online retailer Chemist4U, said: "With the recent price hikes, we're likely to see more and more people turning to unregulated sellers because the medication may be cheaper. "This is extremely unsafe as many of these sources distribute counterfeit versions of Mounjaro, which pose serious risks to your health." The National Pharmacy Association has urged the government to improve regulation around online purchase of weight loss jabs to ensure people get the proper medical advice when buying them. How to spot fake weight loss jabs Chemist4U said there were three main identifiers to suggest a jab is fake. First, cost is a big one, the price of these jabs is set at certain points, with most retailers selling them at only a small profit. If you see one for considerably cheaper than normal, ask yourself how the seller got this from the manufacturer cheaper than large high street chains did. Secondly, currently in the UK Wegovy and Mounjaro are prescription-only medicines and can only be issued after a consultation. You can buy them from stores like Boots or Asda Pharmacy, but they will require a medical consultation first. If a vendor is selling them without this step, then you should steer clear of buying them. Finally, they will also look different. Chemist4U says "the materials used for real pens feel solid and well made, whereas a fake pen is likely to feel cheap, flimsy and have more obvious flaws like uneven colouring, rough edges or loose parts". They also point out that the real pens each have a unique serial number, whereas fake ones will not have one or a fake one.
Medscape
9 hours ago
- Medscape
New First-Line Option for Advanced Bladder Cancer
The National Institute for Health and Care Excellence (NICE) has recommended the combination of enfortumab vedotin (Padcev, Astellas) with pembrolizumab (Keytruda, MSD) as a first-line option for adults with unresectable or metastatic urothelial cancer who are eligible for platinum-based chemotherapy. More than 1200 people in England are expected to benefit each year. Clinical experts described the combination therapy as a "step change" in bladder cancer management. Until now, treatment options for this patient group have seen little meaningful progress since the 1980s. Enfortumab vedotin is an antibody-drug conjugate consisting of an antibody targeting Nectin-4, a protein highly expressed in urothelial carcinoma cells. After binding, it causes the cells to release monomethyl auristatin E, resulting in cell death. Pembrolizumab, its combination partner, is a PD-1 inhibitor. High Disease Burden Urothelial cancer accounts for around 90% of bladder cancers, affecting more than 18,000 people annually in England. Prognosis is poor, with only 10% of patients with stage 4 disease surviving for 5 years or more. Current standard treatments include platinum-based chemotherapy ( cisplatin or carboplatin with gemcitabine), followed by avelumab maintenance therapy if the cancer has not progressed. However, only about 12% of patients see improvement with chemotherapy, underscoring the need for better options. Patient experts described living with metastatic urothelial cancer as "intensely challenging and emotionally exhausting', affecting work, travel, and physical activity. Action Bladder Cancer UK called the announcement a 'very welcome, and significant, step forward for this hard-to-treat cancer'. Clinical Evidence The recommendation in final draft guidance was supported by results from the phase 3 EV-302 trial, which enrolled 886 adults with untreated, unresectable, locally advanced, or metastatic urothelial cancer. Participants were randomly assigned in a 1:1 ratio to receive either enfortumab vedotin–pembrolizumab or standard chemotherapy. Enfortumab vedotin–pembrolizumab nearly doubled the median time to disease progression or death to 12.5 months, compared with 6.3 months for chemotherapy. Median overall survival was also improved, at 33.8 months versus 15.9 months with chemotherapy. Helen Knight, director of medicines evaluation at NICE, said the drug combination is 'highly promising and effective,' adding that these clinical trial results highlight the 'tremendous difference' it could make to the length and quality of people's lives. Cost and NHS Access Enfortumab vedotin is listed at £578 per 20 mg vial or £867 per 30 mg vial. Pembrolizumab costs £2630 per 100 mg vial, excluding VAT. The drugs will be supplied through confidential commercial arrangements with the NHS. NICE's appraisal committee applied a severity modifier, reflecting the high disease burden, and concluded that the therapy met acceptable cost-effectiveness thresholds. The treatment will be available immediately across the NHS in England, with funding required within 90 days of final publication of the guidance.
